Checkpoint Therapeutics Inc (CKPT) — Cash Flow-to-Debt Ratio
Checkpoint Therapeutics Inc (CKPT) has a Cash Flow-to-Debt Ratio of -0.65x as of March 2025, meaning its operating cash flow of $-11.69 Million could theoretically repay -1% of its total liabilities ($17.87 Million) in one year. Check cash flow reinvestment rate of Checkpoint Therapeutics Inc to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Checkpoint Therapeutics Inc Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Checkpoint Therapeutics Inc across 10 annual periods. Also explore Checkpoint Therapeutics Inc total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Checkpoint Therapeutics Inc (2015–2024)
Year-by-year debt coverage analysis for Checkpoint Therapeutics Inc. For market capitalisation and broader financial context, see Checkpoint Therapeutics Inc (CKPT) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.55x | $-31.10 Million | $20.10 Million | ▲ +40.1% |
| 2023 | -2.58x | $-47.59 Million | $18.43 Million | ▼ -47.1% |
| 2022 | -1.76x | $-57.55 Million | $32.77 Million | ▼ -73.5% |
| 2021 | -1.01x | $-26.31 Million | $25.98 Million | ▲ +55.9% |
| 2020 | -2.29x | $-16.55 Million | $7.22 Million | ▲ +12.9% |
| 2019 | -2.63x | $-21.37 Million | $8.12 Million | ▼ -33.6% |
| 2018 | -1.97x | $-25.80 Million | $13.09 Million | ▲ +18.8% |
| 2017 | -2.43x | $-15.46 Million | $6.37 Million | ▲ +10.4% |
| 2016 | -2.71x | $-9.95 Million | $3.67 Million | ▼ -941.0% |
| 2015 | -0.26x | $-1.11 Million | $4.26 Million | — |